Venrock Healthcare Capital Partners II, L.P. 13D and 13G filings for Lyra Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 5:49 pm Sale |
2024-09-30 | 13G | Lyra Therapeutics, Inc. LYRA |
Venrock Healthcare Capital Partners II, L.P. | 1,204,094 1.800% |
-4,349,458 (-78.32%) |
Filing |
| 2024-02-14 8:35 pm Purchase |
2023-12-31 | 13G | Lyra Therapeutics, Inc. LYRA |
Venrock Healthcare Capital Partners II, L.P. | 5,553,552 9.999% |
2,120,284 (+61.76%) |
Filing |
| 2023-02-14 4:40 pm Purchase |
2022-12-31 | 13G | Lyra Therapeutics, Inc. LYRA |
Venrock Healthcare Capital Partners II, L.P. | 3,433,268 9.999% |
218 (+0.01%) |
Filing |
| 2022-04-22 4:05 pm Purchase |
2022-04-12 | 13G | Lyra Therapeutics, Inc. LYRA |
Venrock Healthcare Capital Partners II, L.P. | 3,433,050 9.999% |
3,433,050 (New Position) |
Filing |